表纸
市场调查报告书

抗生素的全球市场:成长,趋势,预测(2019~2024年)

Antibiotics Market - Growth, Trends, and Forecast (2019 - 2024)

出版商 Mordor Intelligence LLP 商品编码 391470
出版日期 内容资讯 英文 116 Pages
商品交期: 2-3个工作天内
价格
Back to Top
抗生素的全球市场:成长,趋势,预测(2019~2024年) Antibiotics Market - Growth, Trends, and Forecast (2019 - 2024)
出版日期: 2019年01月01日内容资讯: 英文 116 Pages
简介

全球抗生素市场,2018年成为426亿5,389万美元规模。该市场今后预计以4%的年复合成长率扩大,到2024年达563亿6,992万美元。

本报告提供全球抗生素市场相关调查,市场趋势与各市场区隔趋势,各地区预测,加入此市场的主要企业的简介等相关资讯汇整。

第1章 简介

第2章 调查方法

第3章 摘要整理

第4章 市场定义趋势

  • 市场概要
  • 推动市场的要素
    • 抗MRSA/VRE药的登场
    • 学名药的开发
    • 脆弱的高龄人口
  • 阻碍市场的要素
    • 对抗生素的抗性
    • 致力于积极研究的企业很少
    • 在法律规章认证上需要的时间
  • 产业的魅力度:波特五力分析

第5章 市场区隔

  • 各产品
    • Cephalosporins
    • Penicillins
    • Fluroquinilones
    • Macrolides
    • Carbapenems
    • Aminoglycosides
    • Sulfonamides
    • 其他
  • 各频谱
    • 广效抗生素
    • 窄效抗生素
  • 各地区
    • 北美
    • 欧洲
    • 亚太地区
    • 中东、非洲
    • 南美

第6章 竞争环境

  • 企业简介
    • GlaxoSmithKline PLC
    • Johnson & Johnson Inc.
    • Merck & Co. Inc.
    • Pfizer Inc.
    • Bayer Healthcare AG
    • Novartis AG
    • Sanofi SA
    • Abbott Laboratories
    • Roche Holding AG

第7章 市场机会与未来趋势

本网页内容可能与最新版本有所差异。详细情况请与我们联系。

目录
Product Code: 49644

Market Summary

The global antibiotics market was valued at USD 42,653.89 million in 2018, and is estimated to be valued at USD 56,369.92 million in 2024, witnessing a CAGR of 4.7%. Certain factors that are driving the market growth include the emergence of anti-MRSA drugs, development of generic drugs, and vulnerable aging population.

A company that initially produced the patented drug tries to generate maximum revenue before the patent expires. Once the patent expires, there will be many competitors who begin manufacturing the generic formulations. They have the same composition and same pharmacological activities as of the original drug. Almost 80% of the prescription antibiotics are generic. As a result of this, the price is reduced. More people can afford drugs, thus, resulting in improved healthcare outcomes. However, indiscriminate drug usage also leads to drug resistance and other complications.

Scope of the Report

As per the scope of the report, antibiotic medicines are among the most prescribed courses worldwide, in fighting bacterial infections, primarily in outpatient settings.

Key Market Trends

Carbapenems are Expected to Show the Rapid Growth of in the Future.

The cephalosporin segment is expected to account for the largest market size during the forecast period. Carbapenems are expected to witness the highest CAGR of around 5.9% during the forecast period.

The rising threat of drug resistance and a weak pipeline of new molecules are leading to the development of combinational formulations. For instance, in countries, like India, the emergence of multi-drug-resistant tuberculosis (TB) is a major factor driving the R&D expenditures. Methicillin-resistant Staphylococcus aureus (MRSA) is another bacterium responsible for several infections in humans that are difficult to treat. The MRSA infection is difficult to treat with standard antibiotics, such as penicillins (methicillin, dicloxacillin, nafcillin, and oxacillin), and the cephalosporins. In 2014, the US Food and Drug Administration (FDA) approved four new antibiotics for the treatment of infections caused by gram-positive bacteria, including MRSA.

North America is Expected to Dominate the Market in the Forcasted Period

North America currently dominates the market for antibiotics and is expected to continue its stronghold for a few more years. This region is expected to increase its market share in the future, owing to the increased adoption of antibiotics. The United States holds the majority of the market in the North American region, due to the fact that the United States has the highest antibiotic prescribing rate in the North American region. In addition, there is a rise in per capita health expenditure in the country, which is expected to increase over the forecast period, owing to decrease in the unemployment rate.

Competitive Landscape

The antibiotics market is highly competitive and consists of several major players. In terms of market share, few of the major players currently dominate the market. However, with technological advancements and product innovations, mid-size to smaller companies are increasing their market presence, by introducing new products with less prices. Companies, like Glaxosmithkline, Pfizer PLC, Bayer AG, Novartis AG, and Abbott Inc., hold significant market shares in the antibiotics market.

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • Report customization as per the client's requirements
  • 3 months of analyst support

Table of Contents

1 INTRODUCTION

  • 1.1 Study Deliverables
  • 1.2 Study Assumptions
  • 1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Emergence of Anti-MRSA/VRE Drugs
    • 4.2.2 Development of Generic Drugs
    • 4.2.3 Vulnerable Aging Population
  • 4.3 Market Restraints
    • 4.3.1 Antibiotic Resistance
    • 4.3.2 Fewer Companies Involved in Active Research
    • 4.3.3 Time Taken for Regulatory Approval
  • 4.4 Industry Attractiveness of Porter's Five Forces Analysis

5 MARKET SEGMENTATION

  • 5.1 By Product Type
    • 5.1.1 Cephalosporins
    • 5.1.2 Penicillins
    • 5.1.3 Fluroquinilones
    • 5.1.4 Macrolides
    • 5.1.5 Carbapenems
    • 5.1.6 Aminoglycosides
    • 5.1.7 Sulfonamides
    • 5.1.8 Other Product Types
  • 5.2 By Spectrum
    • 5.2.1 Broad-spectrum Antibiotics
    • 5.2.2 Narrow-spectrum Antibiotics
  • 5.3 Geography
    • 5.3.1 North America
      • 5.3.1.1 United States
      • 5.3.1.2 Canada
      • 5.3.1.3 Mexico
    • 5.3.2 Europe
      • 5.3.2.1 France
      • 5.3.2.2 Germany
      • 5.3.2.3 United Kingdom
      • 5.3.2.4 Italy
      • 5.3.2.5 Spain
      • 5.3.2.6 Rest of Europe
    • 5.3.3 Asia-Pacific
      • 5.3.3.1 China
      • 5.3.3.2 Japan
      • 5.3.3.3 India
      • 5.3.3.4 Australia
      • 5.3.3.5 South Korea
      • 5.3.3.6 Rest of Asia-Pacific
    • 5.3.4 Middle East & Africa
      • 5.3.4.1 GCC
      • 5.3.4.2 South Africa
      • 5.3.4.3 Rest of Middle East & Africa
    • 5.3.5 South America
      • 5.3.5.1 Brazil
      • 5.3.5.2 Argentina
      • 5.3.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 GlaxoSmithKline PLC
    • 6.1.2 Johnson & Johnson Inc.
    • 6.1.3 Merck & Co. Inc.
    • 6.1.4 Pfizer Inc.
    • 6.1.5 Bayer Healthcare AG
    • 6.1.6 Novartis AG
    • 6.1.7 Sanofi SA
    • 6.1.8 Abbott Laboratories
    • 6.1.9 Roche Holding AG

7 MARKET OPPORTUNITIES AND FUTURE TRENDS

Back to Top